[Perspectives] The fate of sotorasib: a regulatory failure potentially harming patients

April, 04, 2024 | Select Oncology Journal Articles

Sotorasib was the first approved KRAS inhibitor granted marketing authorisation by the US Food and Drug administration (FDA) by use of the accelerated approval pathway for patients with advanced non-small-cell lung cancer (NSCLC) with the KRASG12C mutation. The drug targets a subset of mutations in KRAS—an oncogene considered undruggable for decades—that occur in 14% of patients with NSCLC.2

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy